Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Cellular Tumor Antigen p53 Market Research Report 2019-2025

Request for Sample of this report
Buy now

1 Study Coverage

  • 1.1 Cellular Tumor Antigen p53 Product Introduction
  • 1.2 Market Segments
  • 1.3 Key Cellular Tumor Antigen p53 Manufacturers Covered: Ranking by Revenue
  • 1.4 Market by Type
    • 1.4.1 Global Cellular Tumor Antigen p53 Market Size Growth Rate by Type
    • 1.4.2 COTI-2
    • 1.4.3 D-12PGJ3
    • 1.4.4 APR-246
    • 1.4.5 ATRN-502
    • 1.4.6 Cenersen Sodium
    • 1.4.7 MJ-05
    • 1.4.8 MX-225
    • 1.4.9 Others
  • 1.5 Market by Application
    • 1.5.1 Global Cellular Tumor Antigen p53 Market Size Growth Rate by Application
    • 1.5.2 Ovarian Cancer
    • 1.5.3 Prostate Cancer
    • 1.5.4 Brain Cancer
    • 1.5.5 Others
  • 1.6 Study Objectives
  • 1.7 Years Considered

2 Executive Summary

  • 2.1 Global Cellular Tumor Antigen p53 Market Size, Estimates and Forecasts
    • 2.1.1 Global Cellular Tumor Antigen p53 Revenue 2015-2026
    • 2.1.2 Global Cellular Tumor Antigen p53 Sales 2015-2026
  • 2.2 Global Cellular Tumor Antigen p53, Market Size by Producing Regions: 2015 VS 2020 VS 2026
    • 2.2.1 Global Cellular Tumor Antigen p53 Retrospective Market Scenario in Sales by Region: 2015-2020
    • 2.2.2 Global Cellular Tumor Antigen p53 Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Cellular Tumor Antigen p53 Competitor Landscape by Players

  • 3.1 Cellular Tumor Antigen p53 Sales by Manufacturers
    • 3.1.1 Cellular Tumor Antigen p53 Sales by Manufacturers (2015-2020)
    • 3.1.2 Cellular Tumor Antigen p53 Sales Market Share by Manufacturers (2015-2020)
  • 3.2 Cellular Tumor Antigen p53 Revenue by Manufacturers
    • 3.2.1 Cellular Tumor Antigen p53 Revenue by Manufacturers (2015-2020)
    • 3.2.2 Cellular Tumor Antigen p53 Revenue Share by Manufacturers (2015-2020)
    • 3.2.3 Global Cellular Tumor Antigen p53 Market Concentration Ratio (CR5 and HHI) (2015-2020)
    • 3.2.4 Global Top 10 and Top 5 Companies by Cellular Tumor Antigen p53 Revenue in 2019
    • 3.2.5 Global Cellular Tumor Antigen p53 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Cellular Tumor Antigen p53 Price by Manufacturers
  • 3.4 Cellular Tumor Antigen p53 Manufacturing Base Distribution, Product Types
    • 3.4.1 Cellular Tumor Antigen p53 Manufacturers Manufacturing Base Distribution, Headquarters
    • 3.4.2 Manufacturers Cellular Tumor Antigen p53 Product Type
    • 3.4.3 Date of International Manufacturers Enter into Cellular Tumor Antigen p53 Market
  • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

  • 4.1 Global Cellular Tumor Antigen p53 Market Size by Type (2015-2020)
    • 4.1.1 Global Cellular Tumor Antigen p53 Sales by Type (2015-2020)
    • 4.1.2 Global Cellular Tumor Antigen p53 Revenue by Type (2015-2020)
    • 4.1.3 Cellular Tumor Antigen p53 Average Selling Price (ASP) by Type (2015-2026)
  • 4.2 Global Cellular Tumor Antigen p53 Market Size Forecast by Type (2021-2026)
    • 4.2.1 Global Cellular Tumor Antigen p53 Sales Forecast by Type (2021-2026)
    • 4.2.2 Global Cellular Tumor Antigen p53 Revenue Forecast by Type (2021-2026)
    • 4.2.3 Cellular Tumor Antigen p53 Average Selling Price (ASP) Forecast by Type (2021-2026)
  • 4.3 Global Cellular Tumor Antigen p53 Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)

  • 5.1 Global Cellular Tumor Antigen p53 Market Size by Application (2015-2020)
    • 5.1.1 Global Cellular Tumor Antigen p53 Sales by Application (2015-2020)
    • 5.1.2 Global Cellular Tumor Antigen p53 Revenue by Application (2015-2020)
    • 5.1.3 Cellular Tumor Antigen p53 Price by Application (2015-2020)
  • 5.2 Cellular Tumor Antigen p53 Market Size Forecast by Application (2021-2026)
    • 5.2.1 Global Cellular Tumor Antigen p53 Sales Forecast by Application (2021-2026)
    • 5.2.2 Global Cellular Tumor Antigen p53 Revenue Forecast by Application (2021-2026)
    • 5.2.3 Global Cellular Tumor Antigen p53 Price Forecast by Application (2021-2026)

6 North America

  • 6.1 North America Cellular Tumor Antigen p53 by Country
    • 6.1.1 North America Cellular Tumor Antigen p53 Sales by Country
    • 6.1.2 North America Cellular Tumor Antigen p53 Revenue by Country
    • 6.1.3 U.S.
    • 6.1.4 Canada
  • 6.2 North America Cellular Tumor Antigen p53 Market Facts & Figures by Type
  • 6.3 North America Cellular Tumor Antigen p53 Market Facts & Figures by Application

7 Europe

  • 7.1 Europe Cellular Tumor Antigen p53 by Country
    • 7.1.1 Europe Cellular Tumor Antigen p53 Sales by Country
    • 7.1.2 Europe Cellular Tumor Antigen p53 Revenue by Country
    • 7.1.3 Germany
    • 7.1.4 France
    • 7.1.5 U.K.
    • 7.1.6 Italy
    • 7.1.7 Russia
  • 7.2 Europe Cellular Tumor Antigen p53 Market Facts & Figures by Type
  • 7.3 Europe Cellular Tumor Antigen p53 Market Facts & Figures by Application

8 Asia Pacific

  • 8.1 Asia Pacific Cellular Tumor Antigen p53 by Region
    • 8.1.1 Asia Pacific Cellular Tumor Antigen p53 Sales by Region
    • 8.1.2 Asia Pacific Cellular Tumor Antigen p53 Revenue by Region
    • 8.1.3 China
    • 8.1.4 Japan
    • 8.1.5 South Korea
    • 8.1.6 India
    • 8.1.7 Australia
    • 8.1.8 Taiwan
    • 8.1.9 Indonesia
    • 8.1.10 Thailand
    • 8.1.11 Malaysia
    • 8.1.12 Philippines
    • 8.1.13 Vietnam
  • 8.2 Asia Pacific Cellular Tumor Antigen p53 Market Facts & Figures by Type
  • 8.3 Asia Pacific Cellular Tumor Antigen p53 Market Facts & Figures by Application

9 Latin America

  • 9.1 Latin America Cellular Tumor Antigen p53 by Country
    • 9.1.1 Latin America Cellular Tumor Antigen p53 Sales by Country
    • 9.1.2 Latin America Cellular Tumor Antigen p53 Revenue by Country
    • 9.1.3 Mexico
    • 9.1.4 Brazil
    • 9.1.5 Argentina
  • 9.2 Central & South America Cellular Tumor Antigen p53 Market Facts & Figures by Type
  • 9.3 Central & South America Cellular Tumor Antigen p53 Market Facts & Figures by Application

10 Middle East and Africa

  • 10.1 Middle East and Africa Cellular Tumor Antigen p53 by Country
    • 10.1.1 Middle East and Africa Cellular Tumor Antigen p53 Sales by Country
    • 10.1.2 Middle East and Africa Cellular Tumor Antigen p53 Revenue by Country
    • 10.1.3 Turkey
    • 10.1.4 Saudi Arabia
    • 10.1.5 U.A.E
  • 10.2 Middle East and Africa Cellular Tumor Antigen p53 Market Facts & Figures by Type
  • 10.3 Middle East and Africa Cellular Tumor Antigen p53 Market Facts & Figures by Application

11 Company Profiles

  • 11.1 Advaxis, Inc.
    • 11.1.1 Advaxis, Inc. Corporation Information
    • 11.1.2 Advaxis, Inc. Description and Business Overview
    • 11.1.3 Advaxis, Inc. Sales, Revenue and Gross Margin (2015-2020)
    • 11.1.4 Advaxis, Inc. Cellular Tumor Antigen p53 Products Offered
    • 11.1.5 Advaxis, Inc. Related Developments
  • 11.2 American Gene Technologies International Inc.
    • 11.2.1 American Gene Technologies International Inc. Corporation Information
    • 11.2.2 American Gene Technologies International Inc. Description and Business Overview
    • 11.2.3 American Gene Technologies International Inc. Sales, Revenue and Gross Margin (2015-2020)
    • 11.2.4 American Gene Technologies International Inc. Cellular Tumor Antigen p53 Products Offered
    • 11.2.5 American Gene Technologies International Inc. Related Developments
  • 11.3 Aprea AB
    • 11.3.1 Aprea AB Corporation Information
    • 11.3.2 Aprea AB Description and Business Overview
    • 11.3.3 Aprea AB Sales, Revenue and Gross Margin (2015-2020)
    • 11.3.4 Aprea AB Cellular Tumor Antigen p53 Products Offered
    • 11.3.5 Aprea AB Related Developments
  • 11.4 Cellceutix Corporation
    • 11.4.1 Cellceutix Corporation Corporation Information
    • 11.4.2 Cellceutix Corporation Description and Business Overview
    • 11.4.3 Cellceutix Corporation Sales, Revenue and Gross Margin (2015-2020)
    • 11.4.4 Cellceutix Corporation Cellular Tumor Antigen p53 Products Offered
    • 11.4.5 Cellceutix Corporation Related Developments
  • 11.5 Critical Outcome Technologies Inc.
    • 11.5.1 Critical Outcome Technologies Inc. Corporation Information
    • 11.5.2 Critical Outcome Technologies Inc. Description and Business Overview
    • 11.5.3 Critical Outcome Technologies Inc. Sales, Revenue and Gross Margin (2015-2020)
    • 11.5.4 Critical Outcome Technologies Inc. Cellular Tumor Antigen p53 Products Offered
    • 11.5.5 Critical Outcome Technologies Inc. Related Developments
  • 11.6 Eleos Inc.
    • 11.6.1 Eleos Inc. Corporation Information
    • 11.6.2 Eleos Inc. Description and Business Overview
    • 11.6.3 Eleos Inc. Sales, Revenue and Gross Margin (2015-2020)
    • 11.6.4 Eleos Inc. Cellular Tumor Antigen p53 Products Offered
    • 11.6.5 Eleos Inc. Related Developments
  • 11.7 ORCA Therapeutics B.V.
    • 11.7.1 ORCA Therapeutics B.V. Corporation Information
    • 11.7.2 ORCA Therapeutics B.V. Description and Business Overview
    • 11.7.3 ORCA Therapeutics B.V. Sales, Revenue and Gross Margin (2015-2020)
    • 11.7.4 ORCA Therapeutics B.V. Cellular Tumor Antigen p53 Products Offered
    • 11.7.5 ORCA Therapeutics B.V. Related Developments
  • 11.8 OSE Pharma SA
    • 11.8.1 OSE Pharma SA Corporation Information
    • 11.8.2 OSE Pharma SA Description and Business Overview
    • 11.8.3 OSE Pharma SA Sales, Revenue and Gross Margin (2015-2020)
    • 11.8.4 OSE Pharma SA Cellular Tumor Antigen p53 Products Offered
    • 11.8.5 OSE Pharma SA Related Developments
  • 11.9 PCI Biotech Holding ASA
    • 11.9.1 PCI Biotech Holding ASA Corporation Information
    • 11.9.2 PCI Biotech Holding ASA Description and Business Overview
    • 11.9.3 PCI Biotech Holding ASA Sales, Revenue and Gross Margin (2015-2020)
    • 11.9.4 PCI Biotech Holding ASA Cellular Tumor Antigen p53 Products Offered
    • 11.9.5 PCI Biotech Holding ASA Related Developments
  • 11.10 Quark Pharmaceuticals, Inc.
    • 11.10.1 Quark Pharmaceuticals, Inc. Corporation Information
    • 11.10.2 Quark Pharmaceuticals, Inc. Description and Business Overview
    • 11.10.3 Quark Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
    • 11.10.4 Quark Pharmaceuticals, Inc. Cellular Tumor Antigen p53 Products Offered
    • 11.10.5 Quark Pharmaceuticals, Inc. Related Developments
  • 11.1 Advaxis, Inc.
    • 11.1.1 Advaxis, Inc. Corporation Information
    • 11.1.2 Advaxis, Inc. Description and Business Overview
    • 11.1.3 Advaxis, Inc. Sales, Revenue and Gross Margin (2015-2020)
    • 11.1.4 Advaxis, Inc. Cellular Tumor Antigen p53 Products Offered
    • 11.1.5 Advaxis, Inc. Related Developments
  • 11.12 Shenzen SiBiono GeneTech Co., Ltd.
    • 11.12.1 Shenzen SiBiono GeneTech Co., Ltd. Corporation Information
    • 11.12.2 Shenzen SiBiono GeneTech Co., Ltd. Description and Business Overview
    • 11.12.3 Shenzen SiBiono GeneTech Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)
    • 11.12.4 Shenzen SiBiono GeneTech Co., Ltd. Products Offered
    • 11.12.5 Shenzen SiBiono GeneTech Co., Ltd. Related Developments
  • 11.13 SK Biopharmaceuticals Co., Ltd.
    • 11.13.1 SK Biopharmaceuticals Co., Ltd. Corporation Information
    • 11.13.2 SK Biopharmaceuticals Co., Ltd. Description and Business Overview
    • 11.13.3 SK Biopharmaceuticals Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)
    • 11.13.4 SK Biopharmaceuticals Co., Ltd. Products Offered
    • 11.13.5 SK Biopharmaceuticals Co., Ltd. Related Developments
  • 11.14 Tara Immuno-Oncology Therapeutics LLC
    • 11.14.1 Tara Immuno-Oncology Therapeutics LLC Corporation Information
    • 11.14.2 Tara Immuno-Oncology Therapeutics LLC Description and Business Overview
    • 11.14.3 Tara Immuno-Oncology Therapeutics LLC Sales, Revenue and Gross Margin (2015-2020)
    • 11.14.4 Tara Immuno-Oncology Therapeutics LLC Products Offered
    • 11.14.5 Tara Immuno-Oncology Therapeutics LLC Related Developments
  • 11.15 Z53 Therapeutics, LLC
    • 11.15.1 Z53 Therapeutics, LLC Corporation Information
    • 11.15.2 Z53 Therapeutics, LLC Description and Business Overview
    • 11.15.3 Z53 Therapeutics, LLC Sales, Revenue and Gross Margin (2015-2020)
    • 11.15.4 Z53 Therapeutics, LLC Products Offered
    • 11.15.5 Z53 Therapeutics, LLC Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)

  • 12.1 Cellular Tumor Antigen p53 Market Estimates and Projections by Region
    • 12.1.1 Global Cellular Tumor Antigen p53 Sales Forecast by Regions 2021-2026
    • 12.1.2 Global Cellular Tumor Antigen p53 Revenue Forecast by Regions 2021-2026
  • 12.2 North America Cellular Tumor Antigen p53 Market Size Forecast (2021-2026)
    • 12.2.1 North America: Cellular Tumor Antigen p53 Sales Forecast (2021-2026)
    • 12.2.2 North America: Cellular Tumor Antigen p53 Revenue Forecast (2021-2026)
    • 12.2.3 North America: Cellular Tumor Antigen p53 Market Size Forecast by Country (2021-2026)
  • 12.3 Europe Cellular Tumor Antigen p53 Market Size Forecast (2021-2026)
    • 12.3.1 Europe: Cellular Tumor Antigen p53 Sales Forecast (2021-2026)
    • 12.3.2 Europe: Cellular Tumor Antigen p53 Revenue Forecast (2021-2026)
    • 12.3.3 Europe: Cellular Tumor Antigen p53 Market Size Forecast by Country (2021-2026)
  • 12.4 Asia Pacific Cellular Tumor Antigen p53 Market Size Forecast (2021-2026)
    • 12.4.1 Asia Pacific: Cellular Tumor Antigen p53 Sales Forecast (2021-2026)
    • 12.4.2 Asia Pacific: Cellular Tumor Antigen p53 Revenue Forecast (2021-2026)
    • 12.4.3 Asia Pacific: Cellular Tumor Antigen p53 Market Size Forecast by Region (2021-2026)
  • 12.5 Latin America Cellular Tumor Antigen p53 Market Size Forecast (2021-2026)
    • 12.5.1 Latin America: Cellular Tumor Antigen p53 Sales Forecast (2021-2026)
    • 12.5.2 Latin America: Cellular Tumor Antigen p53 Revenue Forecast (2021-2026)
    • 12.5.3 Latin America: Cellular Tumor Antigen p53 Market Size Forecast by Country (2021-2026)
  • 12.6 Middle East and Africa Cellular Tumor Antigen p53 Market Size Forecast (2021-2026)
    • 12.6.1 Middle East and Africa: Cellular Tumor Antigen p53 Sales Forecast (2021-2026)
    • 12.6.2 Middle East and Africa: Cellular Tumor Antigen p53 Revenue Forecast (2021-2026)
    • 12.6.3 Middle East and Africa: Cellular Tumor Antigen p53 Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

  • 13.1 Market Opportunities and Drivers
  • 13.2 Market Challenges
  • 13.3 Market Risks/Restraints
  • 13.4 Porter's Five Forces Analysis
  • 13.5 Primary Interviews with Key Cellular Tumor Antigen p53 Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis

  • 14.1 Value Chain Analysis
  • 14.2 Cellular Tumor Antigen p53 Customers
  • 14.3 Sales Channels Analysis
    • 14.3.1 Sales Channels
    • 14.3.2 Distributors

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Research Methodology
      • 16.1.1 Methodology/Research Approach
      • 16.1.2 Data Source
    • 16.2 Author Details

    Cellular Tumor Antigen p53 market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Cellular Tumor Antigen p53 market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

    Segment by Type, the Cellular Tumor Antigen p53 market is segmented into
    COTI-2
    D-12PGJ3
    APR-246
    ATRN-502
    Cenersen Sodium
    MJ-05
    MX-225
    Others

    Segment by Application, the Cellular Tumor Antigen p53 market is segmented into
    Ovarian Cancer
    Prostate Cancer
    Brain Cancer
    Others

    Regional and Country-level Analysis
    The Cellular Tumor Antigen p53 market is analysed and market size information is provided by regions (countries).
    The key regions covered in the Cellular Tumor Antigen p53 market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
    The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
    Competitive Landscape and Cellular Tumor Antigen p53 Market Share Analysis
    Cellular Tumor Antigen p53 market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Cellular Tumor Antigen p53 business, the date to enter into the Cellular Tumor Antigen p53 market, Cellular Tumor Antigen p53 product introduction, recent developments, etc.

    The major vendors covered:
    Advaxis, Inc.
    American Gene Technologies International Inc.
    Aprea AB
    Cellceutix Corporation
    Critical Outcome Technologies Inc.
    Eleos Inc.
    ORCA Therapeutics B.V.
    OSE Pharma SA
    PCI Biotech Holding ASA
    Quark Pharmaceuticals, Inc.
    Stemline Therapeutics, Inc.
    Shenzen SiBiono GeneTech Co., Ltd.
    SK Biopharmaceuticals Co., Ltd.
    Tara Immuno-Oncology Therapeutics LLC
    Z53 Therapeutics, LLC

    Buy now